🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchSURMOUNT-MMO: tirzepatide for morbid obesity — anyone have experience? Page 4

SURMOUNT-MMO: tirzepatide for morbid obesity — anyone have experience?

jason_paloalto Wed, Feb 18, 2026 at 8:14 AM 22 replies 986 viewsPage 4 of 5
VendorMark
Senior Member
3,456
14,567
Jan 2024
Texas
Online
Feb 19, 2026 at 12:30 PM#16
PharmHunterJen said:
Whatever the answer turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, and invite the…

This is my experience too, for whatever a second data point is worth.

Last edited: Feb 19, 2026 at 2:30 PM
21 19DebRD_ATL, KristenIndy, MarkLI_maint and 18 others
Reply Quote Save Share Report
Dr.NateNeph
VIP Member
2,987
16,234
Dec 2023
Houston, TX
Feb 19, 2026 at 4:15 PM#17
BethLabQueen said:
The boring version of this is the one that works, and the boring version is: measure a baseline, change one variable, wait, measure again under the…

Agreed on the substance. I would put less weight on the timescale, because two months of anything is not enough to distinguish a trend from a wobble.

Last edited: Feb 19, 2026 at 6:15 PM
22 20NauseaFreeNow, SteveThurs, B12Beth and 19 others
Reply Quote Save Share Report
lisa_labSD
Member
278
1,234
Oct 2024
San Diego, CA
Feb 19, 2026 at 8:00 PM#18
BethLabQueen said:
The boring version of this is the one that works, and the boring version is: measure a baseline, change one variable, wait, measure again under the…

This answered a question I did not know how to ask.

23 21Dr.PulmRoch, maya_sedona, stefan_berlin and 20 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Dr.CardioMD
VIP Member
2,678
14,567
Dec 2023
Cleveland, OH
Feb 19, 2026 at 11:45 PM#19

Adding the clinical framing, because it changes how the question reads. The useful move here is to separate what is established from what is widely repeated. Those two sets overlap less than the confident tone of most write-ups suggests, and the second set is where nearly all the disagreement on this board comes from.

24 22roxy_nash, tony_orlando, Dr.NephBHM_UK and 21 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Feb 20, 2026 at 3:30 AM#20

Moderator note: the sourcing question belongs in the vendor section and has been split out. Tagging this one for the weekly digest.

46 19PurityPaulOR, MaxMetOK, MounjBrad and 43 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register